Journal of Research in Ayurvedic Sciences

Register      Login

VOLUME 1 , ISSUE 1 ( January-March, 2017 ) > List of Articles

RESEARCH ARTICLE

Clinical Efficacy and Safety of Vyoshadi Guggulu and Haritaki Churna in the Management of Obesity: A Prospective Open-label Multicenter Study

KR Kishore, PKS Nair, SK Giri, BS Sharma, MM Padhi

Citation Information : Kishore K, Nair P, Giri S, Sharma B, Padhi M. Clinical Efficacy and Safety of Vyoshadi Guggulu and Haritaki Churna in the Management of Obesity: A Prospective Open-label Multicenter Study. J Res Ayurvedic Sci 2017; 1 (1):17-24.

DOI: 10.5005/jp-journals-10064-0003

License: CC BY 3.0

Published Online: 00-03-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background

Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have a negative effect on health. Obesity is most commonly caused by a combination of excessive food intake, lack of physical activity, and genetic susceptibility. Obesity can be compared with a condition called sthaulya in Ayurveda.

Aims and objectives

To evaluate the efficacy and safety of Vyoshadi Guggulu and Haritaki Churna in patients suffering from obesity (sthaulya).

Materials and methods

A prospective, open-label multicenter study was carried out at three peripheral centers of the Central Council for Research in Ayurvedic Sciences. A total of 165 obese patients satisfying the selection criteria were enrolled from the outpatient department of these centers and were administered Vyoshadi Guggulu (1.5 gm) twice daily before food with lukewarm water and Haritaki Churna (3 gm) twice a day before food for 12 weeks. Patients were also followed after 2 weeks of without medication period. Body mass index (BMI), waist circumference, hip circumference, and 36-item Short Form (SF-36) health survey questionnaire were assessed at an interval of 14 days each till 12 weeks (i.e., 84 days) and at the end of without drug follow-up period at 14th week. Paired sample t-test was used to compare mean change in BMI, waist circumference, and hip circumference from baseline to the 84th day. A p-value <0.05 was considered significant.

Results

At the end of treatment period of 84 days as compared with baseline, a statistically significant change in BMI, waist circumference, hip circumference, and waist–hip ratio was observed (p-value <0.001). A significant reduction in serum cholesterol level was also observed from a mean value of 187.79 at baseline to 183.84 at 84th day (p-value <0.022). Moreover, a significant improvement in all the eight domains of SF-36 health survey questionnaire was also observed (p-value <0.001)

Conclusion

Vyoshadi Guggulu and Haritaki Churna administered together in the above-mentioned dose were found effective and safe in patients suffering from obesity.

How to cite this article

Kishore KR, Ravte RK, Nair PKS, Giri SK, Sharma BS, Dua P, Khanduri S, Yadav B, Rana R, Singhal R, Srikanth N, Padhi MM, Dhiman KS. Clinical Efficacy and Safety of Vyoshadi Guggulu and Haritaki Churna in the Management of Obesity: A Prospective Open-label Multicenter Study. J Res Ayurvedic Sci 2017;1(1):17-24.


PDF Share
  1. Region and country specific information sheets. (The impact of chronic disease in India). Geneva: WHO; 2012. Available from: http://www.who.int/chp/chronic_disease_report/media/india.pdf.
  2. Rising burden of obesity in Asia. J Obes 2010;2010:868573.
  3. Global status report on noncommunicable diseases 2010. Geneva: WHO; 2011. Available from: http://www.who.int/nmh/publications/ncd_report_full_en.pdf.
  4. Trends in diet, nutritional status, and diet-related non-communicable diseases in China and India: the economic costs of the nutrition transition. Nutr Rev 2001 Dec;59(12):379-390.
  5. Obesity in children & adolescents. Indian J Med Res 2010 Nov;132(5):598-607.
  6. The Ayurvedic Pharmacopoeia of India. 1st ed. Part II, Vol II. New Delhi: Department of AYUSH, Ministry of Health and Family Welfare: 2008. p. 138-140.
  7. The Ayurvedic Pharmacopoeia of India. 1st ed. Part I, Vol I. New Delhi: Department of AYUSH, Ministry of Health and Family Welfare; 1989. p. 47-48.
  8. The MOS 36-item short form health survey (SF 36). I. Conceptual framework and item selection. Med Care 1992 Jun;30(6):473-483.
  9. ; Snow, KK.; Kosisnki, M.; Gandek, B. SF-36 health survey manual and interpretation guide. Boston (MA): The Health Institute; 1993.
  10. Pharmacological approaches. In: Kopelman PG, editor. Management of obesity and related disorders. London: Martin Dunitz Ltd; 2001.
  11. Role of vyosadi guggulu in medorog (obesity) associated with dyslipidemia: a case study. Int J Ayurveda Pharma Res 2015 Jan;3(1):78-80.
  12. Effect of piperine in the regulation of obesity-induced dyslipidemia in high-fat-diet rats. Indian J Pharmacol 2011 May;43(3):296-299.
  13. effect of zingiberofficinale supplementation on obesity management with respect to the uncoupling protein 1 -3826A>G and ß3-adrenergic receptor Trp64Arg polymorphism. Phytother Res 2015;2015:25899896.
  14. Effects of three different doses of a fruit extract of Terminaliachebula on metabolic components of metabolic syndrome, in a rat model. Phytother Res 2010 Jan;24(1):107-112.
PDF Share